Prescription Drug Price Reforms Won’t Happen for Years

Prescription Drug Price Reforms Won’t Happen for Years

The two biggest benefits for seniors in the IRA are the Medicare negotiation of certain high-cost prescription drugs, and the $2,000 out-of-pocket cap. But while price negotiations technically start next year, no consumer will see the benefit until the new prices begin in 2026, and even then on only 10 drugs (another 15 are added in 2027 and 2028, rising to 20 by 2029 and subsequent years).

The $2,000 out-of-pocket cap, which is across the board for all seniors, not just on certain drugs, is even worse. That cap doesn’t go into effect until 2025, although out-of-pocket costs get capped at $4,000 in 2024. If there is kind of an explanation for delays in setting up Medicare drug price negotiation, for the out-of-pocket cap there is not. You literally tally up patient out-of-pocket costs, which are fully transparent, until they hit $2,000, and then stop them. Why does this take more than two years to pull off? Medicare itself, the entire program, took only a year to implement.

Other parts of the bill do come online more quickly. The insulin price cap of $35 a month for Medicare recipients starts in 2023, as does free vaccine coverage in Medicare and the rebates on Medicare drugs with price increases above inflation. But the inflation rebate is benchmarked to 2021 prices, locking in those high costs, and just would mute price growth. The real benefits here are Medicare negotiations that lower drug prices, and the cap on all prescription drug costs for seniors. Those are delayed.

It is absolutely insane for a political party to boast that it lowered prices for seniors when the price reductions are years and years down the road. That kind of de facto bait and switch leads to distrust and anger. You’d have thought Democrats would have learned this lesson in the Affordable Care Act, whose major benefits didn’t kick in for four years after passage, a time lag that helped lead to two midterm wipeouts. But here we are again, as Democratic officials tout a drug price reform that isn’t visible to anyone.

That’s not necessarily Democrats’ fault (although they could have ignored the parliamentarian, of course). What is their fault is the failure to immediately make evident the benefits of the policy. Democrats have had a tendency to break faith with their base, to make promises and fail to deliver. Here’s a policy they’ve been promising for nearly two decades, they pass the policy, and they’re going to spend years explaining how the implementation is just around the corner. It comes off as double-talk and toxifies a political brand. And in this case, it was unnecessary.

Read More »

Senate Passes $280 Billion Industrial Policy Bill Meant to Counter China

Senate Passes $280 Billion Industrial Policy Bill Meant to Counter China

The CHIPS and Science Act of 2022 passed in a vote of 63-33, with 17 Republicans voting in favor. The over 1,000-page legislation includes $52.7 billion for direct funding for the construction and expansion of semiconductor manufacturing and $24 billion for tax incentives and other purposes.

The bill will authorize roughly $200 billion in science and technology research funding that will be spread across several government agencies over the next five years. The largest recipient of the research funds will be the National Science Foundation, which will receive $81 billion.

Related:

CHIPS Won’t Help China

Third, the CHIPS Act actually has provisions designed specifically to restrict investments in China. These so-called “guardrails” require that companies taking federal dollars for American projects must also agree not to invest in state-of-the-art technology in China—not just with the federal dollars, with any dollars. Good-faith critics have raised fair concerns that these guardrails should be broader, tougher, and firmer. But any guardrails at all represent unprecedented restrictions on what U.S. companies can do in the People’s Republic. It’s one thing to say an ideal bill would hurt China even more; it’s quite another to try and claim that less-than-perfect restrictions count as “help.”

Pelosi’s Husband Dumped Up to $5M of Tech Stock Right Before Senate Passed CHIPS

Pelosi’s Husband Dumped Up to $5M of Tech Stock Right Before Senate Passed CHIPS

Just before the Senate passed a major bill to subsidize computer chip manufacturers on Wednesday, House Speaker Nancy Pelosi’s (D-California) husband sold thousands of shares of Nvidia — a tech company that could stand to gain from the passage of the nearly $80 billion bill.

Pelosi’s Husband Dumped Up to $5M of Tech Stock Right Before Senate Passed CHIPS

Related:

Nancy Pelosi And Husband Sell NVIDIA Corp Stock After Public Pressure

“I think this comes in response to public pressure and the conflict of interest her stock position posed,” the founder of Congresstrading.com, who asked to remain anonymous due to the sensitive nature of his site, told Benzinga.

“It is surprising to see the sale. Also, what’s surprising here is that she sold and reported one day later. Usually she takes a couple of weeks. She wanted the public to know she cleared her books of this conflict of interest immediately.”

Congresstrading also noted Pelosi’s filings typically come on Fridays, when the media may potentially bury the story over the weekend.

The Nancy Pelosi Tracker on Twitter, which shares transactions by the Speaker of the House, noted the transaction history of NVIDIA Corporation by the Pelosis dates back to May 2021. According to the account, the Pelosis still own 50 options on NVIDIA Corporation with a strike price of $100 and expiration of Sep. 16, 2022 that were purchased back on July 23, 2021.

Pelosi remains one of the most active filers of stock transactions in Congress due to her husband being a venture capitalist.